{"hq_id":"hq-c-org-000072","name":"Bromethalin","context":"human_adult","risk_level":"high","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"high","summary":"Human bromethalin poisoning cases are documented from intentional ingestion and accidental exposure. Clinical toxicity in humans mirrors the neurological syndrome seen in animals: cerebral and spinal cord edema causing progressive neurological deterioration. Cases of human poisoning have been reported in the medical literature and to poison control centers, primarily from intentional ingestion in suicide attempts. Neurological sequelae can be permanent if significant demyelination occurs before treatment. Treatment is supportive; activated charcoal administration early after ingestion may reduce absorption. Corticosteroids and osmotic agents may reduce cerebral edema but have limited evidence base. Bromethalin's lipophilicity and slow elimination from neural tissue mean neurological impairment may persist for months. Long-term outcomes of survivors are poorly documented; a recovery period of months has been reported in subacutely poisoned individuals.","source_refs":["aspca_bromethalin","epa_bromethalin_reg"]},"meta":{"synthesis_version":"n/a","timestamp":"2026-05-01T18:26:20.139Z"}}